Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Stardust Power NASDAQ:SDST$0.50 +0.00 (+0.93%) As of 04:00 PM EasternStardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$28.94 millionConsensus RatingBuyConsensus Price Target$5.11 (+922.7% Upside)Volume225,128 sharesAverage Volume347,824 sharesToday's Range$0.49▼$0.51 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Denison Mines NYSEAMERICAN:DNN$1.41 -0.01 (-0.70%) As of 04:10 PM EasternDenison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.26 billionP/E Ratio-141.00Consensus RatingBuyConsensus Price Target$3.00 (+112.8% Upside)Volume57.10 million sharesAverage Volume30.25 million shares3. Cardiol Therapeutics NASDAQ:CRDL$1.10 -0.05 (-4.35%) As of 04:00 PM EasternCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$90.87 millionP/E Ratio-2.82Consensus RatingBuyConsensus Price Target$8.40 (+663.6% Upside)Volume157,297 sharesAverage Volume382,083 shares4. Quince Therapeutics NASDAQ:QNCX$1.10 -0.03 (-2.65%) As of 04:00 PM EasternQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$48.54 millionP/E Ratio-0.89Consensus RatingBuyConsensus Price Target$8.00 (+627.3% Upside)Volume78,035 sharesAverage Volume248,168 shares5. GeoVax Labs NASDAQ:GOVX$1.01 +0.01 (+1.07%) As of 04:00 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$13.98 millionP/E Ratio-0.18Consensus RatingBuyConsensus Price Target$12.90 (+1,177.2% Upside)Volume245,377 sharesAverage Volume590,731 shares6. Reviva Pharmaceuticals NASDAQ:RVPH$0.89 +0.01 (+1.48%) As of 04:00 PM EasternReviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$41.60 millionP/E Ratio-0.80Consensus RatingBuyConsensus Price Target$10.00 (+1,023.6% Upside)Volume252,433 sharesAverage Volume1.13 million shares7. Immunic NASDAQ:IMUX$0.99 -0.29 (-22.65%) As of 04:00 PM EasternImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$94.87 millionP/E Ratio-0.80Consensus RatingBuyConsensus Price Target$13.20 (+1,233.2% Upside)Volume8.85 million sharesAverage Volume673,085 shares8. Lucid Diagnostics NASDAQ:LUCD$1.25 -0.01 (-0.79%) As of 04:00 PM EasternLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$131.73 millionP/E Ratio-1.10Consensus RatingBuyConsensus Price Target$3.50 (+180.0% Upside)Volume1.08 million sharesAverage Volume470,682 shares9. Ur-Energy NYSEAMERICAN:URG$0.75 0.00 (-0.21%) As of 04:10 PM EasternUr-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$274.02 millionP/E Ratio-5.79Consensus RatingBuyConsensus Price Target$2.30 (+205.6% Upside)Volume2.56 million sharesAverage Volume4.17 million shares10. Western Copper & Gold NYSE:WRN$1.10 0.00 (0.00%) As of 03:59 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$221 millionP/E Ratio-55.25Consensus RatingBuyConsensus Price Target$4.25 (+284.6% Upside)Volume256,746 sharesAverage Volume333,208 shares11. FibroBiologics NASDAQ:FBLG$1.12 +0.08 (+7.69%) As of 04:00 PM EasternFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$42.26 millionP/E Ratio-3.29Consensus RatingBuyConsensus Price Target$13.00 (+1,060.7% Upside)Volume220,327 sharesAverage Volume291,266 shares12. HIVE Digital Technologies NASDAQ:HIVE$1.69 -0.03 (-1.74%) As of 04:00 PM EasternHIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$288.00 millionP/E Ratio-33.80Consensus RatingBuyConsensus Price Target$7.64 (+352.2% Upside)Volume7.60 million sharesAverage Volume6.23 million shares13. Rani Therapeutics NASDAQ:RANI$1.11 0.00 (0.00%) As of 04:00 PM EasternRani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$63.81 millionP/E Ratio-1.05Consensus RatingBuyConsensus Price Target$12.33 (+1,011.1% Upside)Volume90,733 sharesAverage Volume742,424 shares14. ProQR Therapeutics NASDAQ:PRQR$1.66 +0.03 (+1.84%) As of 04:00 PM EasternProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$174.65 millionP/E Ratio-5.19Consensus RatingBuyConsensus Price Target$8.75 (+427.1% Upside)Volume390,104 sharesAverage Volume600,591 shares15. Zura Bio NASDAQ:ZURA$1.54 +0.15 (+10.79%) As of 04:00 PM EasternZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$105.30 millionP/E Ratio-2.91Consensus RatingBuyConsensus Price Target$14.67 (+852.4% Upside)Volume840,526 sharesAverage Volume386,939 shares16. Context Therapeutics NASDAQ:CNTX$0.87 -0.01 (-1.53%) As of 04:00 PM EasternContext Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$77.77 millionP/E Ratio-0.95Consensus RatingBuyConsensus Price Target$6.17 (+611.3% Upside)Volume70,475 sharesAverage Volume408,164 shares17. Aclaris Therapeutics NASDAQ:ACRS$1.38 +0.05 (+3.76%) As of 04:00 PM EasternAclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$149.43 millionP/E Ratio-2.65Consensus RatingBuyConsensus Price Target$11.67 (+745.4% Upside)Volume440,602 sharesAverage Volume1.19 million shares18. Prime Medicine NYSE:PRME$1.73 +0.13 (+8.13%) As of 04:00 PM EasternPrime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More about Prime MedicineMarket Capitalization$226.91 millionP/E Ratio-0.84Consensus RatingBuyConsensus Price Target$13.38 (+673.1% Upside)Volume1.19 million sharesAverage Volume1.21 million shares19. Compass Therapeutics NASDAQ:CMPX$1.86 +0.02 (+1.09%) As of 04:00 PM EasternCompass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass TherapeuticsMarket Capitalization$257.21 millionP/E Ratio-5.03Consensus RatingBuyConsensus Price Target$13.38 (+619.1% Upside)Volume482,278 sharesAverage Volume877,619 shares20. Inozyme Pharma NASDAQ:INZY$1.15 +0.09 (+8.49%) As of 04:00 PM EasternInozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. More about Inozyme PharmaMarket Capitalization$73.88 millionP/E Ratio-0.74Consensus RatingBuyConsensus Price Target$14.63 (+1,171.7% Upside)Volume822,381 sharesAverage Volume463,085 shares21. Acrivon Therapeutics NASDAQ:ACRV$1.40 -0.04 (-2.78%) As of 04:00 PM EasternAcrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$43.89 millionP/E Ratio-0.52Consensus RatingBuyConsensus Price Target$21.80 (+1,457.1% Upside)Volume898,777 sharesAverage Volume182,683 shares22. Century Therapeutics NASDAQ:IPSC$0.54 +0.04 (+7.44%) As of 04:00 PM EasternCentury Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century TherapeuticsMarket Capitalization$46.60 millionP/E Ratio-0.29Consensus RatingBuyConsensus Price Target$4.40 (+712.4% Upside)Volume456,531 sharesAverage Volume432,251 shares23. Cresco Labs OTCMKTS:CRLBF$0.98 +0.13 (+15.52%) As of 03:59 PM EasternCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco LabsMarket Capitalization$478.74 millionP/E Ratio-4.88Consensus RatingBuyConsensus Price Target$3.00 (+207.7% Upside)Volume949,268 sharesAverage Volume660,749 shares24. Lineage Cell Therapeutics NYSEAMERICAN:LCTX$0.50 +0.03 (+5.94%) As of 04:10 PM EasternLineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell TherapeuticsMarket Capitalization$109.99 millionP/E Ratio-4.16Consensus RatingBuyConsensus Price Target$4.20 (+741.7% Upside)Volume1.49 million sharesAverage Volume1.33 million shares25. Caribou Biosciences NASDAQ:CRBU$0.85 0.00 (-0.16%) As of 04:00 PM EasternCaribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. More about Caribou BiosciencesMarket Capitalization$79.14 millionP/E Ratio-0.52Consensus RatingBuyConsensus Price Target$9.33 (+996.9% Upside)Volume786,345 sharesAverage Volume1.57 million shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
